DeepMed Research

NanOlogy, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of NanoPac Intratumoral Injection in Lung Cancer

Phase 2

Completed

Conditions: Neoplasm of Lung
Lung Cancer
Lung Cancer, Nonsmall Cell
Lung Cancer, Small Cell

Interventions: Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension

First Posted Date: 2020-03-19

Last Posted Date: 2023-11-13

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 18

Registration Number: NCT04314895

Locations: 🇺🇸
University of Florida Health, Gainesville, Florida, United States
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Parkview Research Institute, Fort Wayne, Indiana, United States

and more 1 locations

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Phase 1

Withdrawn

Conditions: Kidney Cancer
Adenocarcinoma of Kidney
Adenocarcinoma, Renal
Renal Cell Carcinoma
Renal Cell Cancer

Interventions: Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension

First Posted Date: 2020-02-07

Last Posted Date: 2020-08-04

Lead Sponsor: NanOlogy, LLC

Registration Number: NCT04260360

Trial of NanoPac Focal Therapy for Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer
Prostate Adenocarcinoma
Prostatic Neoplasm
Urogenital Neoplasms
Genital Neoplasms, Male
Prostate Cancer Adenocarcinoma
Localized Cancer

Interventions: Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension

First Posted Date: 2020-01-09

Last Posted Date: 2022-03-29

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 1

Registration Number: NCT04221828

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Missouri, Columbia, Missouri, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 1 locations

Expanded Access to NanoDoce

Conditions: Urogenital Neoplasms

First Posted Date: 2019-08-19

Last Posted Date: 2025-02-26

Lead Sponsor: NanOlogy, LLC

Registration Number: NCT04060628

Expanded Access to NanoPac

Conditions: Locally Advanced Pancreatic Carcinoma
Prostate Cancer
Lung Cancer

First Posted Date: 2018-11-28

Last Posted Date: 2025-02-26

Lead Sponsor: NanOlogy, LLC

Registration Number: NCT03756311

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Phase 1

Completed

Conditions: Urologic Cancer
Bladder Cancer
Urinary Bladder Cancer
Urogenital Neoplasms
Urinary Bladder Neoplasm
Malignant Tumor of the Urinary Bladder
Urologic Neoplasms
Urothelial Carcinoma
Cancer of the Bladder

Interventions: Drug: NanoDoce (direct injection)
Drug: NanoDoce (intravesical instillation) - Visit 2 Instillation
Other: Institutional Standard of Care
Drug: NanoDoce (intravesical instillation) - Induction and Maintenance Instillations

First Posted Date: 2018-08-17

Last Posted Date: 2023-08-14

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 36

Registration Number: NCT03636256

Locations: 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸
BCG Oncology, PC, Phoenix, Arizona, United States
🇺🇸
Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, United States

and more 2 locations

Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Phase 2

Completed

Conditions: Pancreatic Mucinous-Cystic Neoplasm

Interventions: Drug: NanoPac®

First Posted Date: 2017-06-16

Last Posted Date: 2021-06-14

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 20

Registration Number: NCT03188991

Locations: 🇺🇸
Texas Tech University Health Sciences Center, El Paso, Texas, United States
🇺🇸
Parkview Cancer Institute, Fort Wayne, Indiana, United States
🇺🇸
The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States

and more 1 locations

Study of Topical SOR007 Ointment for Cutaneous Metastases

Phase 1

Completed

Conditions: Cutaneous Metastasis

Interventions: Drug: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment

First Posted Date: 2017-04-05

Last Posted Date: 2021-11-05

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 23

Registration Number: NCT03101358

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Phase 2

Completed

Conditions: Locally Advanced Pancreatic Adenocarcinoma

Interventions: Drug: NanoPac®

First Posted Date: 2017-03-13

Last Posted Date: 2024-06-24

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 54

Registration Number: NCT03077685

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Parkview Cancer Institute, Fort Wayne, Indiana, United States

and more 1 locations

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate

Interventions: Drug: NanoPac®

First Posted Date: 2017-03-13

Last Posted Date: 2019-08-20

Lead Sponsor: NanOlogy, LLC

Target Recruit Count: 16

Registration Number: NCT03077659

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy